InnoPharmax
About
About Us
Organization
Our History
News
News
R&D
Pipeline
Anti-infection Agents
Contrast Agents
Oncology Agents
Immunological Agents
Drugs for Rare Diseases
Active Pharmaceutical Ingredient
Products
GemOral
N11005
Technologies
OralPAS®
OralPAS Pro®
MUCR™
Investors
Financial Information
Company Profile
Monthly Revenue
Financial Statements
Corporate Governance
Board Meeting
Committee
Internal Audit
Rule of Procedure
Corporate Social Responsibility
Shareholders Services
Annual Reports
Shareholders' Meetings
Announcements
Contact
Contacts
Contact Information
Career Opportunities
ZH-TW
News
News
News
>
News
>
home
InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride.
On March 26, 2018, InnoPharmax have signed the licensing agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride (BH4) tablets in China and Spain.
On Augest 29, 2022, under the main contract, InnoPharmax and Shandong New Times Pharmaceuticals have signed supplementary agreement to further expend the colaberation regions adding Germany, the United Kingdom and France. The action will facilitate mutual business in European market.
Shandong New Times Pharmaceuticals is one of the members of the Lunan Pharmaceutical Group, a comprehensive pharmaceutical group with integrated production, research and sales of concentrated pharmaceuticals, chemicals and biological products, and is ranked among the top 500 competitive large enterprise groups in China.
Back
uGear Design
-
Website Info.